GSK Ebola vaccine 1st to undergo EMA accelerated procedure
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA) said GlaxoSmithKline's experimental Ebola vaccine is the first product to undergo a new regulatory process aimed at allowing companies developing products against the deadly virus to receive "rapid scientific advice" with the intent of accelerating the assessment processes.